Quantcast
Published On: Fri, Nov 22nd, 2013

FDA approves H5N1 avian influenza vaccine for National Stockpile

The U.S. Food and Drug Administration today approved the first adjuvanted vaccine for the prevention of H5N1 influenza, commonly known as avian or bird flu. The vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, is for use in people 18 years of age and older who are at increased risk of exposure to the H5N1 influenza virus.

H5N1 avian influenza Image/CDC

H5N1 avian influenza
Image/CDC

Avian influenza is an infectious disease of birds caused by certain influenza A viruses. Most avian influenza A viruses do not infect people. However, some viruses, such as H5N1, have caused serious illness and death in people outside of the U.S., mostly among people who have been in close contact with infected and ill poultry. When people do become infected with H5N1, about 60 percent die, according to the World Health Organization. H5N1 is an influenza virus with pandemic potential because it continues to infect wild birds with occasional outbreaks of influenza disease in poultry populations, and most humans have no immunity to it.

“This vaccine could be used in the event that the H5N1 avian influenza virus develops the capability to spread efficiently from human to human, resulting in the rapid spread of disease across the globe,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Vaccines are critical to protecting public health by helping to counter the transmission of influenza disease during a pandemic.”

The H5N1 avian influenza vaccine is not intended for commercial availability. The U.S. Department of Health and Human Services has purchased the vaccine from the manufacturer, ID Biomedical Corporation of Quebec, Quebec City, Canada (a subsidiary of GlaxoSmithKline Biologicals), for inclusion within the National Stockpile for distribution by public health officials if needed.

The vaccine is made using an egg-based manufacturing process, which is also used for ID Biomedical Corporation’s seasonal influenza vaccine, FluLaval. It contains the adjuvant AS03, an oil-in-water emulsion. An adjuvant is a substance incorporated into some vaccines to enhance or direct the immune response of the vaccinated individual. The adjuvant makes it possible to use a small amount of influenza protein per dose of vaccine to elicit the desired immune response in an individual to prevent influenza disease. Reducing the amount of influenza protein per dose helps to increase the total number of doses of a safe and effective vaccine available for the public during a pandemic.

The H5N1 component and the AS03 adjuvant component are supplied in two separate vials, which must be combined prior to use. The vaccine is administered via intramuscular injection in two doses, 21 days apart.

The evaluation of safety compared approximately 3,400 adults 18 years of age and older who received the vaccine to about 1,100 adults who received placebo in a multi-center study. The most common side effect reported during the clinical studies among the vaccine recipients was injection site pain. Muscle aches, headache, fatigue and injection site redness and swelling were also common. To determine how well the vaccine works, the immune response was evaluated in about 2,000 of the vaccinated adults. The results showed that 91 percent of individuals between the ages of 18 and 64 years and 74 percent of individuals 65 years and older who received the two-dose regimen developed antibodies at a level that is expected to reduce the risk of getting influenza.

The manufacturer will collaborate with the FDA and other U.S. governmental agencies on plans to collect additional safety and effectiveness data through U.S. government-sponsored studies of the vaccine, in the event that it is used during an H5N1 influenza virus pandemic.

 

For more infectious disease news and information, visit and “like” the Infectious Disease News Facebook page

Looking for a job in health care? Check here to see what’s available

 

On the DISPATCH: Headlines  Local  Opinion

Subscribe to Weekly Newsletter

* indicates required
/ ( mm / dd ) [ALL INFO CONFIDENTIAL]

About the Author

- Writer, Co-Founder and Executive Editor of The Global Dispatch. Robert has been covering news in the areas of health, world news and politics for a variety of online news sources. He is also the Editor-in-Chief of the website, Outbreak News Today and hosts the podcast, Outbreak News Interviews on iTunes, Stitcher and Spotify Robert is politically Independent and a born again Christian Follow @bactiman63

Tags
Displaying 7 Comments
Have Your Say
  1. CDC releases statement on Canadian H5N1 avian influenza case - The Global Dispatch says:

    […] state authorities regarding control measures if needed. Long-term preparedness measures against H5N1 include the existence of a stockpile of H5N1 vaccine in the Strategic National […]

  2. FDA approves H5N1 avian influenza vaccine for N... says:

    […] The U.S. Food and Drug Administration today approved the first adjuvanted vaccine for the prevention of H5N1 influenza, commonly known as avian or bird flu. The vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, is for use in people 18 years of age and older who are at increased risk of exposure to the H5N1 influenza virus.  […]

  3. GlaxoSmithKline’s N1 Bird Flu Vaccine Gets FDA Approval – NASDAQ | Amazing News says:

    […] The Global Dispatch […]

  4. US FDA approves GSK's bird flu vaccine for national stockpile – Reuters | HNP says:

    […] The Global Dispatch […]

  5. US FDA approves GSK’s bird flu vaccine for national stockpile – Reuters | Weight Loss Diet Plan says:

    […] stockpileFiercePharmaGlaxo Wins U.S. Approval for Bird Flu VaccineBloombergChicago Tribune -The Global Dispatch -Healioall 115 news […]

  6. US FDA approves GSK's bird flu vaccine for national stockpile – Reuters | RHN says:

    […] stockpileFiercePharmaGlaxo Wins U.S. Approval for Bird Flu VaccineBloombergChicago Tribune -The Global Dispatch -Healioall 115 news […]

  7. US FDA approves GSK's bird flu vaccine for national stockpile – Reuters | HNP says:

    […] stockpileFiercePharmaGlaxo Wins U.S. Approval for Bird Flu VaccineBloombergChicago Tribune -The Global Dispatch -Healioall 115 news […]

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Sign up for our Weekly Newsletter



Categories

Archives

At the Movies

Pin It